NVO: Unlocking diabetes treatment breakthroughs now!

Novo Nordisk A/S (NYSE: NVO) is a Danish pharmaceutical leader that has transformed diabetes care for decades and is now at the forefront of a breakthrough in obesity treatments. The company’s market capitalization recently surged so much that it exceeded Denmark’s entire GDP, briefly making Novo Nordisk the most valuable company in Europe (^[1]). This reflects investor excitement over its blockbuster GLP-1 medicines (like Ozempic® for diabetes and Wegovy® for weight loss) which have driven extraordinary growth. Below we dive into Novo Nordisk’s dividend policy, financial leverage, valuation, and the risks and questions facing this soaring healthcare giant.

Dividend Policy & History

Novo Nordisk has a shareholder-friendly capital return policy centered on steady dividends and share buybacks. The company targets a “competitive payout ratio” relative to pharma peers (^[2]). In practice, Novo has paid out around 50% of annual net profit as dividends consistently in recent years (^[2]). For example, the total dividend for 2023 was DKK 9.40 per share, up 52% from 2022’s DKK 6.20, maintaining a ~50% payout ratio (peer pharma average ~46.5%) (^[2]). Novo distributes dividends semi-annually, with an interim payment in August and a final payout in March of the following year (^[2]) (^[2]). Notably, 2023’s interim dividend was DKK 3.00 and the final proposed was DKK 6.40, together comprising the DKK 9.40 per share total (^[2]).

This generous dividend growth has translated into a dividend yield in the 3–4% range recently (^[3]). The yield was modest when the stock hit all-time highs (dropping below 2% at peak prices), but after the subsequent share pullback it has risen closer to mid‐single digits (^[3]). Even so, the yield remains moderate – a sign that investors are valuing Novo more for its growth prospects than for immediate income. Importantly, the dividends are well-covered by earnings and cash flow. The payout ratio was ~50% of net profit in 2023 (^[2]), and even including buybacks, the total cash returned to shareholders (~DKK 61.7 billion) amounted to about 90% of the year’s free cash flow (DKK 68.3 billion) (^[2]). This high cash return suggests management is confident in the business’s ability to continue generating strong cash flows, while still retaining some funds for reinvestment.

Novo Nordisk complements dividends with substantial share repurchases, which enhance total shareholder yield. In 2023, it bought back ~DKK 29.9 billion worth of stock (^[2]). The combination of a ~3–4% dividend yield and ongoing buybacks has yielded an attractive total shareholder return. Going forward, investors can likely expect Novo to continue raising its dividend in line with earnings growth (while keeping the ~50% payout policy) and executing buybacks as excess cash allows.

Leverage & Debt Maturities

Despite its rapid growth and expansion plans, Novo Nordisk maintains a very conservative balance sheet. The company carries relatively modest debt and has historically financed growth largely from internal cash generation. Total borrowings stood at about DKK 27 billion at end of 2023 (approximately $4 billion) (^[2]). This is small relative to Novo’s equity base and annual EBITDA, reflecting a low leverage profile. In fact, Novo Nordisk’s debt-to-equity ratio is under 60% and net debt is minimal thanks to substantial cash reserves (^[4]).

The bulk of Novo’s debt consists of a few euro-denominated bonds issued at extremely low interest rates during the low-rate environment. The company’s outstanding Eurobonds total €2.8 billion, with maturities staggered over the coming years (^[2]). Notably, Novo has a €650M 0.000% coupon bond due June 2024, a €500M 0.750% bond due March 2025, and additional small bonds maturing in 2027, 2028, and 2030 (all carrying coupons around 1% or less) (^[2]). These ultra-low rates underscore Novo’s strong credit standing.

Near-term debt maturities are very manageable. For instance, the 2024 and 2025 bond repayments (DKK ~4.8B and DKK ~3.7B, respectively) are easily covered by Novo’s annual operating cash flow (which exceeded DKK 100B in 2023) (^[2]) (^[2]). Novo Nordisk also retains substantial liquidity through cash on hand and undrawn credit facilities (EUR 1.55B bank facility) as backup (^[2]). With interest expenses of only DKK 542 million in 2023 (^[2]), the company’s interest coverage is exceptionally high – operating profit covers interest well over 100 times. In short, Novo faces no issues meeting its debt obligations; it arguably carries less leverage than its capacity, given its cash generation and AA-rated profile.

This financial strength gives Novo flexibility to invest in growth (or withstand any setbacks) without needing to tap equity markets or take on risky debt loads. Management’s discipline here is evident: issuing debt chiefly when rates were near zero, and otherwise keeping a lean balance sheet. The low leverage and long-dated debt maturities represent a credit strength and reduce risk for equity holders. Novo Nordisk could likely fund its planned expansions (such as new factories) through internal cash flow, but it has the headroom to raise additional debt cheaply if needed. Overall, leverage is a non-issue – if anything, Novo is under-leveraged relative to many large pharma peers.

Coverage and Liquidity

Novo Nordisk’s coverage ratios underscore its robust financial footing. As noted, interest coverage is enormous: with DKK 102.6 billion in 2023 operating profit against only DKK 0.54 billion in interest expense, Novo’s EBIT/interest ratio is nearly 190 times (^[2]) (^[2]). Even on a net income basis, interest was well under 1% of profits. This means the company’s earnings could drop dramatically and it would still comfortably service debt – a testament to Novo’s low debt burden and strong profit margins.

Dividend coverage is also healthy. The ~50% payout ratio implies earnings cover the dividend about 2x over (^[2]). In cash terms, free cash flow exceeded total dividends paid by a comfortable margin (FCF was 108.9B DKK vs. 41.99B DKK dividends in 2023) (^[2]). Even after accounting for share buybacks, Novo generated a slight surplus of cash. The “cash payout ratio” was ~85%, meaning dividends were well within cash flow capacity (^[3]). Novo’s policy of keeping payout around half of profit leaves the remainder to reinvest or repurchase shares – a balanced approach that maintains a cushion.

From a liquidity standpoint, Novo Nordisk is in excellent shape. Year-end cash and equivalents were ~DKK 14.4 billion (^[2]), and that is after heavy buybacks and dividends. The current ratio is on the low side (below 1.0) (^[4]) mainly because high profitability lets Novo operate with negative working capital (e.g. it collects cash quickly and can pay suppliers later). There’s no liquidity crunch since cash conversion is strong and significant credit lines are available if timing issues ever arose.

In sum, Novo Nordisk’s earnings, cash flows, and balance sheet easily cover all fixed obligations – interest, debt maturities, and dividends. The company has ample financial flexibility to continue its dividend/buyback programs and fund expansion initiatives simultaneously. Such strong coverage and liquidity metrics are a key comfort for investors, especially as Novo embarks on ramping up production capacity to meet demand (discussed more under Risks).

Valuation and Comparative Metrics

After its remarkable stock run-up on the success of Ozempic and Wegovy, Novo Nordisk trades at a premium valuation relative to historical norms and many peers. As of year-end 2023, NVO’s price-to-earnings ratio was about 37× (trailing EPS) (^[5]). This is well above the company’s own 5- or 10-year average P/E, which often ranged in the mid-teens to low-20s before the recent boom (^[5]). For perspective, in 2018 Novo traded around 16× earnings (^[5]); today’s multiple implies investors are paying a rich price for the growth fueled by GLP-1 drugs.

Novo’s premium can be put in context: high-growth pharma peers with coveted drug franchises have also seen multiple expansion. For example, Eli Lilly – Novo’s key rival in diabetes/obesity – traded at much higher P/Es (well over 40–50× in 2023) amid excitement for its GLP-1 drug Mounjaro and other pipeline assets (^[6]). So while Novo at ~37× earnings is pricey by traditional pharma standards, it was still somewhat below Lilly’s peak valuation. Traditional big pharma (with slower growth, e.g. insulin franchises or legacy drugs) often trade at low-teens P/Es, which makes Novo’s valuation stand out as aggressive. On a price-to-sales basis, NVO is also elevated – roughly 10× sales (DKK 232B revenue vs ~$300B market cap around early 2024), reflecting its high margins and growth prospects.

If we consider growth-adjusted metrics, Novo’s valuation can be rationalized though not cheap. Earnings per share jumped ~52% in 2023 (^[2]), and consensus anticipated strong double-digit growth ahead (though likely moderating from the 2023 surge). The stock’s PEG ratio (P/E to growth) was roughly near 1.0–1.2 range at times, suggesting the high P/E was somewhat justified by high growth. Additionally, Novo boasts exceptional profitability (40%+ operating margin (^[2]) and ~30%+ net margin (^[2])) and return on capital metrics, which support a higher multiple. ROIC exceeded 50% pre-GLP1 boom and likely even higher post-Wegovy launch (^[7]) – meaning Novo efficiently translates revenues into profit, warranting a quality premium.

That said, the valuation leaves little room for error. The stock’s run made it one of the largest healthcare companies globally, and as mentioned, the most valuable in Europe at one point (^[1]). Any signs of growth slowdown or issues (see Risks) could trigger multiple compression. Indeed, after peaking in mid-2024, Novo’s share price later pulled back sharply (over 40% off highs by late 2024) as exuberance cooled – bringing the forward P/E down to the mid-teens again (^[5]). This illustrates how swiftly sentiment (and valuation) can swing for a hot biotech story. Comparing to competitors, Eli Lilly has since overtaken Novo in obesity drug momentum, and investors have rotated accordingly (^[6]). Novo Nordisk now trades more in line with a solid growth pharma than an extreme momentum stock.

From a dividend yield perspective, the current ~3% yield is actually relatively high for Novo historically (it was <2% at the peak when the stock price was lofty) (^[3]). The free cash flow yield – a useful metric given Novo’s strong cash conversion – is also in the low-single-digits (FCF yield ~2% at the prior high, improving toward ~4–5% after the pullback). These figures are not bargain territory, but for a company expected to continue growing and with such franchises, they can be acceptable.

In summary, Novo Nordisk’s valuation surged to premium levels on the back of its GLP-1 breakthrough, and while it has since corrected somewhat, the stock is still not cheap by conventional metrics. Investors are effectively pricing in sustained growth in the diabetes/obesity market and Novo’s dominant position therein. The key question (next) is whether the company can meet those high expectations – failure to do so might pressure the valuation further, whereas continued clinical and commercial success could arguably keep Novo in an elite valuation bracket.

Key Risks

While Novo Nordisk’s outlook is bright, investors should be mindful of several risks and potential headwinds:

– Product Concentration & Competition: Novo is now heavily dependent on its GLP-1 franchise (semaglutide-based drugs) which accounts for an estimated 70%+ of revenue. This creates concentration risk – any safety scare or loss of exclusivity for Ozempic/Wegovy would severely impact sales. Rival pharmaceutical companies are aggressively targeting this lucrative market. Eli Lilly’s tirzepatide (Mounjaro/Zepbound) has shown even greater weight-loss efficacy and is rapidly gaining share (^[8]). Lilly’s success (it recently surpassed Novo in obesity drug sales momentum) underscores that competition is intensifying in diabetes and obesity treatments (^[8]). Other players (Pfizer, Amgen, etc.) are developing oral GLP-1 pills or next-gen therapies. Novo must continue innovating (e.g. its next-gen CagriSema combination) to defend its lead.

– Supply Chain and Manufacturing Constraints: Surging demand for Novo’s injectables has created periodic supply shortages. The company has openly acknowledged “continued periodic supply constraints and drug shortage notifications” for Ozempic and Wegovy across markets (^[2]). This means Novo hasn’t fully capitalized on demand due to production limitations. It is investing heavily to expand capacity (e.g. constructing a $4 billion plant in North Carolina to produce more GLP-1 drugs) (^[9]). Still, short-term shortages could frustrate patients and physicians, opening the door for competitors or compounded (unofficial) versions of semaglutide in the interim (^[8]). Execution risk exists in scaling up manufacturing fast enough to meet global demand without quality issues.

– Regulatory and Pricing Pressure: Novo Nordisk’s therapies command high prices, especially in the U.S., which invites scrutiny. Insulin, a longstanding product line, has faced intense criticism for price increases historically. Novo (along with peers) recently had to cut U.S. insulin prices and cap out-of-pocket insulin costs at $35/month under public and political pressure (^[10]). Going forward, pricing pressure could extend to GLP-1 drugs as their widespread use strains payer budgets. Indeed, Novo announced price reductions for Wegovy and Ozempic – cutting monthly cost ~30% (from $499 to $349) – amid mounting pressure from insurers and consumers (^[10]). Government actions, like potential Medicare negotiations or inclusion of obesity drugs in insurance coverage mandates, could either squeeze prices or limit reimbursement. Price controls in other major markets (Europe, China) are also a constant factor. In short, Novo may not be able to sustain premium pricing indefinitely, which would affect margins.

– Legal and Liability Risks: The huge patient uptake of GLP-1 medications has brought legal challenges. Novo Nordisk (and Lilly) face numerous product liability lawsuits alleging that use of Ozempic, Wegovy, and other GLP-1 drugs caused serious side effects (e.g. gastrointestinal issues) (^[2]). Plaintiffs claim problems like persistent vomiting or stomach paralysis. Novo asserts that these claims are without merit and does not expect material financial impact from the suits (^[2]). However, litigation outcomes are uncertain and could lead to reputational damage or settlement costs. Separately, regulatory investigations are ongoing (e.g. a U.S. DOJ inquiry into past marketing practices for Ozempic/Rybelsus) (^[2]). While Novo has navigated compliance well historically, any adverse findings or future safety issues (like rare side effects emerging in post-marketing) pose a risk.

– Market Saturation and Long-Term Efficacy: The growth story is heavily dependent on obesity treatments being a long-term, mass market. There are questions about how sustainable the weight-loss drug “boom” will be. For example, will patients stay on Wegovy chronically (it requires ongoing use to maintain weight loss), or will many discontinue due to side effects or cost? If real-world adherence or outcomes disappoint, the ultimate market size could be lower than expected. Moreover, by mid-2024 we saw that even Novo’s next big candidate (CagriSema) did not vastly exceed expectations in trials, reminding investors that pipeline success is not guaranteed (a Phase 3 result in late 2024 showed slightly lower efficacy than hoped, which punished the stock). Thus, any sign of growth faltering – whether due to market saturation, competition, or pipeline setbacks – could sharply impact Novo’s high valuation.

– Macroeconomic and Currency Factors: Novo is a global business, and over half of its sales are in the United States (with the rest across Europe, Asia, etc.). Currency fluctuations can impact reported financials – e.g. a stronger Danish krone (or euro) against the dollar can reduce DKK-reported revenue growth. Novo Nordisk hedges many of its cash flows, but currency swings remain a modest risk to earnings (^[2]). Additionally, broader macroeconomic issues (recession, healthcare budget cuts) could temper demand for expensive drugs or make insurers more cost-conscious. A notable anecdote: Novo has grown so rapidly that it significantly uplifted Denmark’s GDP growth in 2023 (^[11]); if that trend reverses, it could likewise soften an element supporting European markets.

– Ownership Structure (Governance): One structural consideration: Novo Nordisk is effectively controlled by the Novo Nordisk Foundation, which holds all the high-vote A-shares (28% of total shares but 77% of votes) (^[1]). This stable ownership by a foundation can be positive for long-term orientation, but it also means ordinary shareholders have limited influence on corporate matters. There’s little risk of hostile takeover or drastic strategic shifts without the Foundation’s approval. While not a “red flag” per se, this governance setup could be viewed as a minor risk if the Foundation’s interests ever diverged from public shareholders (so far they have been aligned, focusing on sustainable growth and R&D).

Overall, Novo Nordisk’s risk profile is relatively balanced for a high-growth pharma – execution and market risks exist, but the company’s strong finances provide resilience. Investors should monitor how competition, production scaling, and regulatory landscapes evolve, as these factors will determine if Novo can continue its winning streak.

Red Flags and Watch Items

Beyond the broad risks above, a few specific red flags or areas of concern stand out when analyzing NVO:

– Sky-High Market Expectations: The stock’s meteoric rise priced in a lot of good news. This heightens the risk of disappointment. The valuation still assumes robust growth and near-flawless execution – any hiccup (clinical trial miss, regulatory delay, etc.) can trigger outsized stock drops. The recent volatility (shares falling ~20–30% on pipeline news late 2024) underscores how quickly sentiment can swing when expectations are lofty. Investors should be cautious of potential over-optimism around the “miracle” obesity drug narrative.

– GLP-1 Class Effects & Safety Signals: With millions now taking GLP-1 agonists for diabetes or weight loss, rare adverse effects might emerge. There have been reports of things like pancreatitis, gallbladder issues, and even an increased risk of suicidal thoughts (for some obesity meds). While no definitive causal links have derailed the class so far, any serious safety recall or new black-box warning would be a red flag. Product liability lawsuits (as noted) are a canary in the coal mine; even if Novo expects no material impact, the situation bears watching (^[2]) (^[2]). Continued pharmacovigilance is crucial.

– Capacity vs. Demand Mismatch: Novo’s manufacturing capacity needs to catch up to unprecedented demand. If production delays persist, Novo could “leave money on the table” and also risk customer impatience. Competitors (and compounding pharmacies) are ready to fill any gap. The company is investing in new plants and even acquiring manufacturing capabilities (e.g. via its Novo Holdings arm) (^[9]) (^[12]), but execution risk exists. Any sign that Novo cannot manufacture enough Wegovy/Ozempic to meet demand in coming years would be a red flag for its growth trajectory.

– US Payer Coverage for Obesity: One key swing factor is insurance coverage of obesity medications in the U.S. Historically, Medicare and some insurers did not cover weight-loss drugs. Novo’s growth has so far been driven by out-of-pocket payers and limited coverage. If insurers refuse broad reimbursement for Wegovy (due to cost), sales could plateau, or Novo might be forced to give steep discounts. Conversely, if coverage expands it’s a boon – but often at the expense of price. This binary outcome (coverage vs. no coverage) is a wild card. Investors should watch policy developments, such as the potential Treat and Reduce Obesity Act in Congress, etc. Lack of coverage would signal a red flag for the total addressable market.

– Foundation Control and Leadership Changes: As mentioned, the Novo Nordisk Foundation’s control means traditional shareholder activism or takeover discipline is absent. The company will not be easily pressured into short-term moves. While generally stable, this could mask any internal issues – for example, if there were underperformance, the usual market mechanisms (like activist investors pushing for change) are less applicable. Additionally, Novo saw a CEO change in 2025 (Lars Fruergaard Jørgensen stepped down amid the share price slump) (^[13]). A sudden leadership change can be a red flag, though in this case a seasoned insider took over and it was presented as a planned transition. Still, whenever a high-flying company hits turbulence and changes CEO, it’s something to monitor in case of strategic shifts or execution challenges under new management.

In summary, most of Novo’s “red flags” tie back to its phenomenal recent success – high expectations, heavy reliance on one drug platform, and growing pains in scaling up. These are not red flags of distress, but rather caution signs that the company has to clear a very high bar to justify its valuation and sustain momentum. Investors should keep these watch items in mind as Novo navigates its next phase.

Open Questions and Outlook

Finally, here are some open questions for Novo Nordisk’s future that investors and analysts are pondering:

– Can Novo Sustain its Growth Trajectory? – With Ozempic and Wegovy driving unprecedented revenue growth, can Novo keep up the pace as the base gets larger? The company forecasts solid growth (e.g. >20% operating profit growth at constant exchange in 2024) (^[2]), but will growth moderate in subsequent years or can new patient populations (e.g. earlier-stage obesity treatments, broader global rollout) maintain momentum?

– How Will the Next-Generation Pipeline Perform? – A lot is riding on pipeline candidates like CagriSema (a combination GLP-1 + amylin analog for even greater weight loss) and Insulin icodec (a once-weekly insulin). These aim to further “unlock” diabetes and obesity treatment breakthroughs. Will CagriSema deliver superior results to fend off Lilly’s next dual/triple agonists? Early data was mixed, so Phase 3 outcomes are crucial. Similarly, can a weekly insulin attract broad adoption from patients and payers? The clinical and commercial success of these pipeline projects will shape Novo’s post-2025 growth (^[8]).

– Is the Obesity Drug Market a Fad or a New Standard? – There’s little doubt that GLP-1 drugs are effective for weight loss, but open questions remain on long-term market dynamics. Will physicians eventually reserve these drugs for the most at-need patients, or are we heading toward a world where tens of millions use them preventively? Also, how will patient and payer attitudes evolve as more data on lifetime benefits/costs accumulates? The ultimate size of the obesity therapy market (a potential hundreds of billions opportunity) is yet to be determined by societal and medical trends.

– How Will Payers and Governments React? – An unanswered question is whether broad insurance coverage for obesity medications will happen in major markets. If Medicare and private insurers embrace covering drugs like Wegovy for the masses, Novo’s volume could explode (albeit at negotiated prices). If they do not, uptake could be slower and more limited to affluent/self-pay patients. Additionally, government policy (price negotiations, healthcare reforms) could either expand or limit Novo’s opportunities. The U.S. policy on obesity drug reimbursement is a key wildcard in the next few years.

– Can Novo Nordisk Diversify Beyond GLP-1? – While dominating diabetes and obesity is a enviable position, Novo risks being viewed as a “one-trick pony” if all its fortunes tie to GLP-1. The company does have other segments – e.g. hemophilia drugs (NovoSeven/NovoEight), growth hormone therapies, etc. – but these are relatively small now. Will Novo seek to acquire or develop new therapeutic areas to broaden its portfolio? Its R&D is starting to venture into adjacent fields (like cardiovascular outcomes for obesity, NASH, kidney disease). An open question is whether management will use its strong cash flows to make a significant acquisition to diversify, or double-down on metabolic diseases. Thus far, Novo has favored internal R&D and smaller bolt-ons over big M&A.

– What is the Endgame for Capital Allocation? – Novo Nordisk generates huge profits and, as seen, returns most of it to shareholders. Is this the optimal use of capital long-term? Open questions remain on whether Novo should be investing even more aggressively (in manufacturing, R&D, talent) given the scale of the opportunity, rather than distributing ~90% of free cash flow back via buybacks/dividends (^[2]). Conversely, if growth eventually slows, will Novo consider further increasing payouts or one-time special dividends? The balance between reinvestment and returns will be an ongoing strategic debate, especially with the Foundation’s influence (which may prioritize sustainable growth and scientific investments).

In conclusion, Novo Nordisk stands at the crossroads of remarkable opportunity and significant responsibility. The company’s breakthroughs are transforming treatment for two of society’s biggest health challenges – diabetes and obesity – and investors have rewarded it with a premium valuation. Going forward, executing on manufacturing expansion, fending off competitors, and delivering new innovations will be essential to unlock the next leg of value. Novo’s fundamental financial health (strong profits, low debt) gives it a solid foundation to take on these challenges. The coming years will reveal whether Novo Nordisk can extend its 100-year legacy of “driving change” and live up to the sky-high expectations now set by the market. The potential is enormous, but so are the hurdles – making NVO a fascinating story to watch for growth-oriented investors, with a mix of promising upside and important open questions to monitor.

Sources:

1. Novo Nordisk Annual Report 2023 – SEC Form 20-F (^[2]) (^[2]) (^[2]) (^[2]) (^[2]) (^[2]) 2. Novo Nordisk Investor Relations – Dividend Policy and 2023 payout details (^[2]) (^[2]) (^[2]) 3. Yahoo Finance / YCharts – Novo Nordisk key financial metrics and dividend yield (^[3]) (^[3]) (^[4]) 4. Novo Nordisk Annual Report 2023 – Financial statements (debt, interest, cash flow) (^[2]) (^[2]) (^[2]) 5. Macrotrends – Historical P/E ratios for NVO (^[5]) (^[5]) 6. Nasdaq/Zacks analysis – Competition from Eli Lilly and GLP-1 market dynamics (^[8]) (^[8]) 7. Axios News – Wegovy supply constraints and expansion plans (^[9]) 8. AP/News outlets – Drug pricing pressures and recent price cuts (^[10]) (^[10]) 9. Wikipedia (Novo Nordisk page) – Market cap context and ownership structure (^[1]) (^[1]) 10. Company statements – Product sales performance (Ozempic, Wegovy) and guidance (^[2]) (^[2]) (^[2])

Sources

1. https://en.wikipedia.org/wiki/Novo_Nordisk
2. https://sec.gov/Archives/edgar/data/353278/000162828024002635/nvo-20231231_d2.htm
3. https://simplywall.st/stocks/bg/pharmaceuticals-biotech/bul-nov/novo-nordisk-shares/dividend
4. https://uk.finance.yahoo.com/quote/NVO/key-statistics/
5. https://macrotrends.net/stocks/charts/NVO/Novo%20Nordisk/pe-ratio
6. https://cincodias.elpais.com/opinion/2025-04-29/el-nuevo-orden-de-los-farmacos-antiobesidad.html
7. https://cincodias.elpais.com/opinion/2025-07-31/novo-nordisk-afronta-una-dieta-drastica-y-prolongada.html
8. https://nasdaq.com/articles/can-nvo-defend-its-obesity-lead-glp-1-competition-intensifies
9. https://axios.com/2024/06/24/novo-nordisk-ozempic-wegovy-shortages-north-carolina-plant
10. https://axios.com/2025/11/17/ozempic-wegovy-glp-1-prices
11. https://cincodias.elpais.com/opinion/2025-11-06/las-claves-novo-nordisk-ya-no-es-el-unico-gallo-en-el-corral-de-la-obesidad.html
12. https://axios.com/2024/02/05/wegovy-maker-inks-165-billion-deal-to-boost-supply-of-the-weight-loss-drug
13. https://apnews.com/article/f725a97267e34781ea8dfafa3f82ae5c

For informational purposes only; not investment advice.